See more : Wooshin Systems Co., Ltd. (017370.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Contineum Therapeutics, Inc. Class A Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Mullen Group Ltd. (MLLGF) Income Statement Analysis – Financial Results
- Salon Media Group, Inc. (SLNM) Income Statement Analysis – Financial Results
- The Okinawa Electric Power Company, Incorporated (9511.T) Income Statement Analysis – Financial Results
- AS VEF (UIJ.MU) Income Statement Analysis – Financial Results
- Arogo Capital Acquisition Corp. (AOGOW) Income Statement Analysis – Financial Results
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 50.00M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 329.00K | 0.00 |
| Gross Profit | 50.00M | -329.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% |
| Research & Development | 27.60M | 16.89M | 22.36M |
| General & Administrative | 6.32M | 5.83M | 6.29M |
| Selling & Marketing | 0.00 | -329.00K | 0.00 |
| SG&A | 6.32M | 5.50M | 6.29M |
| Other Expenses | 0.00 | -92.00K | -91.00K |
| Operating Expenses | 33.92M | 22.39M | 28.65M |
| Cost & Expenses | 33.92M | 22.72M | 28.65M |
| Interest Income | 4.61M | 761.00K | 77.00K |
| Interest Expense | 208.00K | 388.00K | 332.00K |
| Depreciation & Amortization | 195.00K | 329.00K | 325.00K |
| EBITDA | 23.57M | -23.54M | -28.34M |
| EBITDA Ratio | 47.15% | 0.00% | 0.00% |
| Operating Income | 16.08M | -22.72M | -28.65M |
| Operating Income Ratio | 32.15% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.09M | -1.53M | -354.00K |
| Income Before Tax | 23.17M | -24.25M | -29.00M |
| Income Before Tax Ratio | 46.34% | 0.00% | 0.00% |
| Income Tax Expense | 450.00K | 0.00 | 241.00K |
| Net Income | 22.72M | -24.25M | -29.00M |
| Net Income Ratio | 45.44% | 0.00% | 0.00% |
| EPS | 1.36 | -0.97 | -1.74 |
| EPS Diluted | 1.28 | -0.97 | -1.63 |
| Weighted Avg Shares Out | 16.67M | 25.13M | 16.67M |
| Weighted Avg Shares Out (Dil) | 17.76M | 25.13M | 17.76M |
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics to Attend Upcoming Investor Conferences
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
Source: https://incomestatements.info
Category: Stock Reports